Praxis Precision Medicines, Inc.
General ticker "PRAX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.1B (TTM average)
Praxis Precision Medicines, Inc. follows the US Stock Market performance with the rate: 37.4%.
Estimated limits based on current volatility of 3.0%: low 342.70$, high 361.40$
Factors to consider:
- Total employees count: 116 (+41.5%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Capital depletion risk, Regulatory and compliance, Clinical trial failure, Market competition, Intellectual property risks
- Current price 43.5% above estimated high
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [71.97$, 249.15$]
- 2026-12-31 to 2027-12-31 estimated range: [29.68$, 114.18$]
Financial Metrics affecting the PRAX estimates:
- Negative: with PPE of -21.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3.88 <= 0.28
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of -4.85 <= -4.49
- Negative: Shareholder equity ratio, % of 93.63 > 63.63
- Negative: -0.75 < Inventory ratio change, % of 0
- Negative: negative Industry operating income (median)
Short-term PRAX quotes
Long-term PRAX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2.45MM | $8.55MM | $0.00MM |
| Operating Expenses | $128.82MM | $208.72MM | $326.20MM |
| Operating Income | $-126.37MM | $-200.16MM | $-326.20MM |
| Non-Operating Income | $3.10MM | $17.35MM | $22.93MM |
| R&D Expense | $86.77MM | $152.41MM | $267.12MM |
| Income(Loss) | $-123.28MM | $-182.82MM | $-303.27MM |
| Net Income(Loss)* | $-123.28MM | $-182.82MM | $-303.27MM |
| Stockholders Equity | $69.67MM | $445.45MM | $878.14MM |
| Assets | $87.95MM | $483.11MM | $937.91MM |
| Operating Cash Flow | $-111.14MM | $-131.76MM | $-249.07MM |
| Capital expenditure | $0.05MM | $0.00MM | $0.06MM |
| Investing Cash Flow | $38.95MM | $-248.49MM | $-311.15MM |
| Financing Cash Flow | $91.87MM | $514.32MM | $702.17MM |
| Earnings Per Share** | $-18.69 | $-10.21 | $-13.48 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.